Tonix PharmaceuticalsTNXP
About: Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
Employees: 103
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
21% more funds holding
Funds holding: 24 [Q2] → 29 (+5) [Q3]
4.03% less ownership
Funds ownership: 4.68% [Q2] → 0.65% (-4.03%) [Q3]
42% less capital invested
Capital invested by funds: $227K [Q2] → $132K (-$95.4K) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for TNXP.
Financial journalist opinion
Based on 7 articles about TNXP published over the past 30 days
